Later, leaders from Sofinnova Investments, Blueprint Medicines, BioLineRx USA, and Dynavax should have a lively discussion about Independent Pathways to Commercial Success for Biotech Companies, and look out for the panel later on Oncology's Next Frontier, featuring speakers from Loxo@Lilly, Larkspur Bioscience, AbbVie, Merck Research Laboratories, and Abdera Therapeutics, which will cover antibody-drug conjugates (ADCs), Radiopharma, a and the future of cancer treatment.

In A Look at Biopharma M&A and Shifting Deal Dynamics, industry leaders from Merck, Avenzo Theraputics and Astellas Pharma will examine the intricacies of biopharma transactions and a future of regulatory challenges and changed market forces.